Life Sciences Daily Summary
Life Sciences Daily Summary: What Happened on November 17, 2026
FDA rejects Summit’s ivonescimab application over survival data
Johnson & Johnson and Lilly agreed to multibillion-dollar acquisitions. Seawolf and Commit raised capital for drug programs.
Today in brief
Summit’s ivonescimab application for EGFR-mutated lung cancer did not clear the FDA’s bar for a statistically significant overall-survival benefit.12 Johnson & Johnson will pay $2.2 billion upfront for Ollin, while Lilly’s agreement to acquire Calytrix could reach $1.5 billion.34 Seawolf raised $100 million and entered a Sanofi partnership with potential payments of up to $1.2 billion. Commit raised $60 million for COM002.56
FDA rejects Summit’s ivonescimab application
The FDA rejected Summit Therapeutics’ application for ivonescimab with chemotherapy in locally advanced or metastatic non-small cell lung cancer after patients’ EGFR-mutated disease progressed on tyrosine kinase inhibitor treatment.27
In the Phase 3 HARMONi trial, ivonescimab improved progression-free survival, but the primary overall-survival analysis did not reach statistical significance.78 Median overall survival was 16.8 months with ivonescimab and 14.0 months with chemotherapy alone, with a P value of .0570.7
The FDA said the progression-free survival result did not establish a favorable benefit-risk profile without a statistically significant overall-survival improvement.27 Summit said it would continue developing ivonescimab, which Akeso developed and which is authorized for certain uses in China.27
J&J pays $2.2 billion upfront for Ollin’s late-stage eye drug
Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2 billion upfront, with up to $1.125 billion more tied to regulatory and commercial milestones.39 Ollin’s lead candidate, OLN324, is a bispecific antibody in Phase 3 development for wet age-related macular degeneration and diabetic macular edema.310
OLN324 targets VEGF and Ang2, pathways also targeted by Roche’s Vabysmo.310 Ollin reported that a Phase 1b comparison found numerically greater vision improvement and faster, greater structural changes with OLN324 than with Vabysmo.10
Johnson & Johnson will take responsibility for the pivotal trials. Blackstone Life Sciences will provide up to $750 million for late-stage development.310
Lilly agrees to acquire Calytrix for up to $1.5 billion
Eli Lilly agreed to acquire Calytrix Bio in a deal worth up to $1.5 billion, including an upfront payment and further payments tied to clinical and regulatory milestones.411 Calytrix is developing an antibody against Type 1 and Type 2 mutant calreticulin for essential thrombocythemia and myelofibrosis, blood cancers driven by abnormal blood-cell production.4
Calytrix says the antibody is designed to target mutant cells while sparing healthy tissue and normal blood-cell production.4 Founded in 2025, Calytrix will have Lilly advance the program through clinical development, Lilly said.4
Seawolf raises $100 million and signs Sanofi partnership
Seawolf Therapeutics emerged from stealth with $100 million in seed and Series A financing and signed an exclusive research and licensing deal with Sanofi.5 The deal covers treatments for bleeding disorders and other undisclosed conditions. Seawolf may earn research, development and commercial milestone payments, plus royalties.5
Seawolf’s TRIDENT platform uses lipid nanoparticles to deliver DNA that encodes a therapeutic protein into cell nuclei.5 The company says the approach is intended to support longer-lasting protein production and allow repeat dosing. Seawolf has reported proof of concept in mice and nonhuman primates.5
Commit Biologics raises $60 million for COM002
Commit Biologics raised a $60 million seed round led by Ackermans & van Haaren, with existing investors Novo Holdings, Bioqube Ventures and Korys participating.6 AbbVie Ventures and M Ventures joined the company’s shareholder base in the financing.6
Commit plans to use the proceeds for regulatory filing preparations and other work before testing COM002 in people.6 The company reported that COM002 depleted B cells in human whole-blood experiments and that one dose sustained depletion for more than four weeks in nonhuman primates.6 These preclinical findings precede Commit’s plan to dose its first patient in early 2028.6
Also worth knowing
-
P
The FDA cleared Roche’s Wilserdly, bringing the company into the oral selective estrogen receptor degrader market.12
-
B
The FDA approved Roche’s Gazyva to induce proteinuria remission in adults with primary membranous nephropathy at risk of progression.8
-
B
The FDA approved AstraZeneca’s weekly self-injected Klygefa for adults with anti-AChR antibody-positive generalized myasthenia gravis.8